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The aim of the CARPE registry is to investigate charac-
teristics and medical care in patients affected by chronic 
hand eczema. Patients are assessed by dermatological 
examination and patient questionnaire. Socio-economic 
and clinical data are collected, and quality of life is mea-
sured using the Dermatology Life Quality Index (DLQI). 
A total of 1,163 patients with chronic hand eczema were 
eligible for analysis (mean age 47.0 years; 54.6% female; 
mean disease duration 7.6 years). At inclusion, chronic 
hand eczema was very severe in 23.4%, severe in 47.0%, 
moderate in 20.1%, and clear or almost clear in 9.6% of 
patients. Median DLQI was 8.0. In all, 93.8% of patients 
reported use of topical corticosteroids, 25.6% systemic 
antihistamines, 28.3% topical calcineurin-inhibitors, 
38.0% ultraviolet phototherapy, and 35.3% systemic 
treatment (19.7% alitretinoin) prior to inclusion in the 
registry. A significant proportion of patients may not re-
ceive adequate treatment according to the guideline on 
management of hand eczema. Key words: registry; chro-
nic hand eczema; health services research; systemic thera-
py; health-related quality of life.
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Hand eczema (HE) represents one of the most frequent 
diseases of the skin (1–3). According to a review of 
population-based studies, the point prevalence of HE is 
estimated at approximately 4%, and the 1-year prevalence 
at approximately 10% (4). The review identified female 
gender, the presence of a contact allergy, atopy, and 
exposure to wet work as important risk factors for HE. 
As a disease entity, HE is not homogenous, but varies 
in terms of aetiology and morphology, necessitating 
complex differential diagnostics. Based on aetiology, the 
German guideline on management of HE (International 
Classification of Diseases (ICD-10) numbers: L20, L23, 
L24, L25, L30) differentiates irritant HE, allergic HE, 
atopic HE, protein contact dermatitis, and other forms of 
HE (genuine pompholyx type, tylotic, others) (5). Based 
on morphology, dyshidrotic (vesicular) HE, HE with 
erythema and scaling, hyperkeratotic-rhagadiform (tylo-
tic) and nummular HE are differentiated. The severity of 
HE ranges from mild forms to severe chronic forms that 
require sick leave and can be partly refractory to therapy. 
The proportion of severe chronic HE (CHE) is estimated at 
approximately 5–7% and the proportion of patients refrac-
tory to topical therapy is estimated at approximately 2–4% 
(6). Health-related quality of life (HRQoL) is negatively 
affected in individuals with HE (7) and has a high socio-
economic significance. Occupational skin diseases, most 
frequently manifesting on the hands, rank first among all 
occupational diseases in many countries (8).
Despite a multitude of therapeutic options, therapy 
for CHE remains a challenge (6). There is a notable lack 
of long-term data on the effectiveness and safety of the 
various treatment options for CHE. Therapy registries 
allow the collection of such data under routine condi-
tions, thereby providing important insights that are not 
available from randomized controlled trials.
In the light of this paucity of long-term data on 
CHE the CARPE registry (German acronym CARPE: 
Chronisches Handekzem-Register zum Patienten-Lang-
zeitmanagement, equivalent to: Chronic Hand Eczema 
Registry on Long-Term Patient Management) has been 
established in Germany since 2009 under the auspices 
of the German Dermatological Society (9).
We previously reported baseline data on the first 515 
patients who were included in the registry (9). The aim 
of this paper is to present updated data from the registry, 
including socio-demographic and clinical characteris-
tics, as well as data on the provision of medical care. In 
addition, data on HRQoL are reported for the first time.
MATERIALS AND METHODS 
The CARPE registry was initiated as a prospective registry 
study and does not include any interventional component, in-
vasive measures, or direct comparisons of therapies. Detailed 
information on the project is available at http://carpe.dermis.
net. Any practicing dermatologist in Germany (either in private 
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practice or in hospital) is eligible to participate. The methodo-
logy of the registry has been reported previously (9). Patients 
with CHE treated by a dermatologist in Germany are eligible 
for inclusion in the registry if the following criteria are met: 
(i) disease duration >3 months or >2 flares within the previous 
12 months; (ii) previous treatment with topical corticosteroids; 
(iii) no long-lasting healing under adequate topical treatment 
including corticosteroids; and (iv) no other dominating active 
severe skin diseases or acute skin infections.
The documentation in the CARPE registry is based on a 
physician questionnaire (which can be completed on paper or 
online) and a patient questionnaire. After inclusion (T0) patients 
are followed-up in pre-specified time intervals after 3 (T1), 6 
(T2), 12 (T3), 18 (T4), and 24 (T5) months. Fig. 1 illustrates 
the design of the CARPE registry.
Data reported in this paper relate to the baseline assessment 
(T0). The severity of CHE is assessed using a Physician Global 
Assessment (PGA), supported by a validated photographic guide 
(10). Atopy criteria are recorded using the Erlangen atopy score 
(11, 12). The atopy score is a summary score of clinical and 
cutaneous signs and symptoms of atopy, which is designed to 
measure an atopic skin diathesis. Six diagnostic categories are 
provided to classify hand eczema, representing both aetiological 
(irritant contact dermatitis, allergic contact dermatitis, atopic 
hand eczema) and morphological categories (vesicular dermatitis, 
hyperkeratotic dermatitis, fingertip dermatitis). Data are presen-
ted in a table, as multiple answers were possible. 
HRQoL is measured by the german version of the Derma-
tology Life Quality Index (DLQI) (13). The DLQI consists 
of 10 items and has a recall period of 1 week. Each item is 
answered on a 4-point scale and has a “not applicable” option. 
Total DLQI score is obtained by summing individual item 
scores. The maximum score is 30 and the minimum score is 
0. Higher scores indicate greater impairment in quality of life. 
The following banding is used to derive clinically meaningful 
DLQI categories according to Hongbo et al. (14): DLQI scores 
0–1 = no effect on patient’s life; 2–5 = small effect on patient’s 
life; 6–10 = moderate effect on patient’s life; 11–20 = very large 
effect on patient’s life; and 21–30 = extremely large effect on 
patient’s life. 
Data management and statistical analysis
Data were entered and stored in a Microsoft Access 2003 
database. Data were entered twice and plausibility checks 
were performed as measures of quality assurance. Analyses of 
quantitative and qualitative variables were carried out using 
SAS (version 9.2) and SPSS (version 20) for Windows. Quanti-
tative variables were summarized by mean, median and standard 
deviation (SD). Qualitative variables are summarized by counts 
and percentages. All summary statistics refer to a total number 
of patients of n = 1,163, unless otherwise indicated.
RESULTS
Socio-demographic and clinical findings
The 1,163 CHE patients were recruited by a total of 95 
centres, including 69 practices and 26 hospitals. Of these, 
54.6% were female. Mean (age was 47.0 ± 13.7 years, age 
range 17.1–84.3 years, median: 48.9 years). Mean dura-
tion of hand eczema was 7.6 years (SD 9.1, median 3.8 
years, n = 1,154). Mean body mass index (BMI) was 26.7 
(SD 4.6, median 26.0) kg/m2 (n = 1,157). Of the included 
patients, 32.2% (n = 1,157) had received in-patient treat-
ment (hospital treatment or rehabilitation measure) prior 
to inclusion in the registry, and 81.6% were currently 
gainfully employed (of these, 24.3% (N = 944) were cur-
rently unable to work, and 36.1% had been on sick leave 
due to HE in the past 12 months (N = 944)). Overall, 5.1% 
had lost or changed their occupation due to HE. Table 
I lists the occupations of the included patients. Nursing 
and healthcare, metal and electrical industry and food 
industry and catering were the most frequent occupations. 
The most frequently reported localization was on 
the palm of the hand, while the least frequently repor-
ted localization was the wrist. In terms of other body 
localizations, the forearm was affected in 12.7% of 
patients, and the feet were affected in 72.9%. Irritant 
contact dermatitis was the most frequently occurring 
diagnosis (45.1%), followed by hyperkeratotic-rhaga-
diform (34.0%) and atopic hand eczema (34.0%). Of 
the 1,163 patients, 572 had a monodiagnosis (49.2%). 
Hyperkeratotic-rhagadiform hand eczema was the most 
frequent monodiagnosis (n = 198).
An atopic skin diathesis was present in 41.2% of 
patients and was unclear in 9.7%. In 53.3% of patients, 
patch testing had been performed in the 12 months before 
inclusion in the registry. In 47.8% a type IV sensitization 
had been diagnosed previously. In 40.4% of 
the patients prick testing had been performed 
in the 12 months prior to inclusion. In 40.1% 
of the patients mycological diagnostics had 
been performed, of which findings were 
positive in 8.0%.
Chronic hand eczema severity, itch and 
HRQoL
According to PGA, CHE was rated as very 
severe in 23.4%, severe in 47.0%, mode-
rate in 20.1%, almost clear in 8.1%, and 
clear in 1.5% (n = 1,160). Overall, 81.3% 
of the patients reported pruritus, with mild 
pruritus being the most common (34.2%). 
23.7% reported severe, 23.7% moderate, Fig. 1. Study design of the CARPE registry.
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and 18.3% no itching. Of the patients with severe 
pruritus, 42.3% had atopic hand dermatitis and 37.9% 
irritant hand dermatitis. Median DLQI for the whole 
group of CHE patients was 8.0 (mean: 8.80, SD 6.3, 
n = 992). The spread of DLQI is illustrated in fig. 2. 
Reported medical therapy in the 12 months before 
inclusion in the registry
Overall, use of topical corticosteroids was reported in 
93.8% of patients in the 12 months prior to inclusion 
in the registry. use of systemic antihistamines was 
reported in 25.6%, use of topical calcineurin-inhibitors 
in 28.3%, use of uV phototherapy in 38.0% and use of 
systemic treatment (except antihistamines) in 35.3%.
Further details of reported therapy with topical corti-
costeroids, topical therapy other than topical corticos-
teroids, ultraviolet (uV) therapy and systemic therapy 
are shown in Table III.
DISCUSSION
In their commentary on the significance of patient 
registries for dermatological disorders, de Souza & 
Rangel Miller (15) distinguish several objectives of pa-
tient registries, namely to: (i) characterize and describe 
the experiences of affected individuals; (ii) identify 
patients and treating physicians; (iii) assist the deve-
lopment of clinical care guidelines and improvements 
in care quality and disease outcome; (iv) encourage 
research, including genotype-phenotype correlations, 
and publication; (v) collect and store DNA and other 
biological/tissue samples from affected and unaffected 
family members; and (vi) collect post-marketing sur-
veillance data for approved drugs
The data presented in this paper relate to objective 
(i), as we aimed to comprehensively characterize and 
describe the experience of patients affected by CHE. 
Mean disease duration was almost 8 years and CHE was 
graded as very severe or severe in approximately 70% of 
affected patients. Furthermore, approximately one-third 
of all patients had already received in-patient treatment 
and 36% had been on sick leave in the 12 months prior to 
inclusion in the registry. These data confirm severity and 
chronicity of CHE in affected patients. In Germany the 
social security system covers treatment of severe occupa-
tional skin disease (OSD) by means of interdisciplinary 
in-patient rehabilitation measures with the goal of avoi-
ding loss or change of job (16, 17). The comparatively 
high figure for in-patient treatment can thus be explained 
by the fact that specialized centres for occupational der-
matology offering such rehabilitation 
measures contribute significantly to 
the CARPE registry. 
Further evidence for the impair-
ment entailed by CHE stems from 
the analysis of the DLQI data. A 
Swedish study in 100 patients with 
hand eczema found a median DLQI of 
6.0 (18), hence less QoL impairment 
compared with our data. However, a 
European multicentre study in 416 
patients with hand eczema from 10 
European patch test clinics found 
exactly the same median DLQI as in 
our study, i.e. 8.0 (19). 
Several studies have investigated 
HRQoL in occupational hand eczema/
Table I. Most frequent occupations among the 944 subjects n = 944
Current occupation %
Nursing and healthcare 20.9
Metal and electrical industry 18.1
Food industry and catering 13.8
Office work, administration 10.2
Cleaning 5.6
Hairdressers and beauticians 5.4
Construction 5.3
Printing, chemical, textile and plastic industry 4.3
Distribution, warehouse 2.3
Motor vehicle operator 1.6
Agriculture, animal farming 1.6
Table II. Localization and diagnoses of chronic hand eczema
Patients, %
Localization (n = 1,160)
Palm 84.7




Diagnosis (n = 1,163)
Irritant contact dermatitis 45.1
Atopic hand eczema 34.0
Hyperkeratotic hand eczema 34.0
Vesicular hand eczema 27.7
Allergic contact dermatitis 22.3
Fingertip dermatitis 7.7
Fig. 2. Distribution of the Dermatology Life Quality Index. Number of patients are given.
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contact dermatitis, and generally found lower estimates 
compared with our study. A study from the uk exami-
ned 70 patients with occupational contact dermatitis and 
found a median DLQI score of 5 (20). A Danish study 
included 758 patients with occupational hand eczema 
and reported a median DLQI of 5.5 for all patients and 
7.8 for severe cases (21). A median DLQI score of 
4.5 was found in a study in patients with occupational 
contact dermatitis from Australia (22). The more pro-
nounced impairment of HRQoL found in this study in 
comparison to estimates reported in the literature again 
confirms severity and chronicity of CHE, as defined by 
the inclusion criteria for the CARPE registry.
Overall, 41% of patients had an atopic background 
and a type IV sensitization was reported in 48% of 
patients. Atopic hand eczema and allergic contact der-
matitis were, however, reported in 34% and 22%. These 
data underline the multifactorial aetiology of CHE (23), 
which often results from the interplay of endogenous 
factors (atopic skin diathesis, genetic factors, such as 
filaggrin loss-of-function mutations (24)) and exoge-
nous factors (allergens, irritants).
Ninety-four percent of patients included had been 
treated with topical corticosteroids in the 12 months 
preceding inclusion in the registry. This figure con-
firms the inclusion criteria, which include “previous 
treatment with corticosteroids”, as outlined above. 
38% had received uV phototherapy, which is recom-
mended as treatment step 2 for moderate-to-severe 
hand eczema in the guidelines on the management 
of hand eczema (5). Systemic immunomodulating 
therapy (e.g. alitretinoin, systemic corticosteroids, and 
cyclosporine) is recommended additionally in step 3 
if HE is persistent or chronically relapsing. Thirty-five 
percent had received some form of systemic treatment 
(except oral antihistamines); hence systemic treatment 
might be underutilized in CHE. A myriad of reasons may 
account for this finding. Systemic treatment may predo-
minantly have been used for those patients with the most 
severe CHE (23.4% had very severe CHE) or the most 
pronounced impairment in HRQoL (33.9% had a DLQI 
≥11). Patients from occupational dermatology centres may 
have received comprehensive measures of secondary and 
tertiary prevention before or instead of systemic treatment. 
Many patients were included in the CARPE registry when 
treatment by alitretinoin had just become available in 
Germany in 2008 and practical experience was limited. 
There is no evidence-base for the use of oral antihis-
tamines in the management of CHE, which is in cont-
rast to the 26% of patients who report having received 
oral antihistamines. Oral antihistamines are probably 
prescribed for the itch associated with CHE, but the 
pathogenesis of itch involves many other mediators, 
such as proteases. 
Strengths and weaknesses
The strength of the CARPE registry study is the com-
prehensive assessment of the medical history, current 
skin lesions, and medical care by a physician questionn-
aire, in parallel with an assessment of quality of life and 
satisfaction with care by a patient questionnaire. This 
allows to capture both the dermatologists’ as well as the 
patients’ perspectives. The assessments are carried out 
at regular intervals, which allows to evaluate the natural 
history of disease over time, as well as an investigation 
of the comparative effectiveness of various therapeutic 
options. Prospective data will be reported in the future.
Looking at the participating centres it becomes evi-
dent that a number of centres that contribute a signifi-
cant proportion of the patients included in the CARPE 
registry are centres with a special focus in occupational 
dermatology. Patients with occupational CHE and se-
vere forms of CHE thus seem to be overrepresented in 
the CARPE registry. It is, however, difficult to judge 
the degree of selection bias that may have occurred, as 
there are no robust population-based data on the cha-
racteristics of CHE in the general population. It would 
have been of value to collect blood samples for genetic 
analyses and to screen for psychiatric co-morbidities. 
However, the value of potentially important information 
needs to be weighed against the fact that a multi-centre 
registry will be successful only if the burden for phy-
sicians and patients is acceptable.
Table III. Reported treatments in the past 12 months (n = 1,163)
Topical Patients, % ultraviolet therapy Patients, % Systemic treatment Patients, %
Corticosteroids Bath Psoralen plus ultraviolet A 5.5 Acitretin 2.7
Highly potent 26.8 Cream Psoralen plus ultraviolet A 32.0 Alitretinoin 19.7
Potent 62.8 Other ultraviolet therapies 4.7 Antihistamines 25.6
Average 52.7 Systemic Psoralen plus ultraviolet A 0.3 Cyclosporine 1.9
Mild 16.2 Methotrexate 0.4
Calcineurin inhibitors 28.3 Corticosteroids 14.4
Iontophoresis therapy 5.0





aOther topical therapies include for instance topical antibiotics, antimycotics or antiseptics.
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Conclusion
It proved feasible to implement a prospective CHE re-
gistry study in Germany. Both subjective and objective 
parameters confirm the chronicity and severity of CHE. 
A multitude of therapeutic options are reported in CHE 
patients. A significant proportion of patients may not 
receive adequate treatment. Future research will need 
to make use of longitudinal data to study the course of 
the disease and the effectiveness of different therapies 
in a comparative manner.
ACKNOWLEDgEMENTS
The authors are indebted to all the dermatologists who, with 
great commitment, have contributed to the CARPE registry 
project (available from http://www.medicaljournals.se/acta/co
ntent/?doi=10.2340/00015555-1632). 
Funding source: The CARPE registry is funded by the German 
Dermatological Society and supported by Basilea Pharmaceutica. 
Conflicts of interest: CA, SM, EW, VM, PE, TR and TLD re-
ceived honoraria and lecture fees from Basilea Pharmaceutica. 
Ab received lecture fees from basilea, Meda, Astellas, Novartis 
and GlaxoSmithkline. MW declares no conflicts of interest. 
REfERENCES
1. Meding B, Jarvholm B. Incidence of hand eczema – a 
population-based retrospective study. J Invest Dermatol 
2004; 122: 873–877.
2. Meding B, Wrangsjo k, Jarvholm B. Fifteen-year follow-
up of hand eczema: persistence and consequences. Br J 
Dermatol 2005; 152: 975–980.
3. Apfelbacher CJ, Radulescu M, Diepgen TL, funke U. Oc-
currence and prognosis of hand eczema in the car industry: 
results from the PACO follow-up study (PACO II). Contact 
Dermatitis 2008; 58: 322–329.
4. Thyssen JP, Johansen JD, Linneberg A, Menne T. The epide-
miology of hand eczema in the general population – preva-
lence and main findings. Contact Dermatitis 2010; 62: 75–87.
5. Diepgen TL, Elsner P, Schliemann S, fartasch M, Kollner 
A, Skudlik C, et al. Guideline on the management of hand 
eczema ICD-10 Code: L20. L23. L24. L25. L30. J Dtsch 
Dermatol Ges 2009; 7 Suppl 3: S1–16.
6. Diepgen TL, Agner T, Aberer W, berth-Jones J, Cambazard 
F, Elsner P, et al. Management of chronic hand eczema. 
Contact Dermatitis 2007; 57: 203–210.
7. Moberg C, Alderling M, Meding B. Hand eczema and 
quality of life: a population-based study. Br J Dermatol 
2009; 161: 397–403.
8. Diepgen TL. Occupational skin-disease data in Europe. Int 
Arch Occup Environ Health 2003; 76: 331–338.
9. Apfelbacher CJ, Akst W, Molin S, Schmitt J, Bauer A, Weiss-
haar E, et al. CARPE: a registry project of the German Derma-
tological Society (DDG) for the characterization and care of 
chronic hand eczema. J Dtsch Dermatol Ges 2011; 9: 682–688.
10. Coenraads PJ, Van Der Walle H, Thestrup-Pedersen k, 
Ruzicka T, Dreno b, De La Loge C, et al. Construction and 
validation of a photographic guide for assessing severity of 
chronic hand dermatitis. Br J Dermatol 2005; 152: 296–301.
11. Diepgen TL, fartasch M, Hornstein OP. Evaluation and 
relevance of atopic basic and minor features in patients 
with atopic dermatitis and in the general population. Acta 
Derm Venereol 1989; Suppl 144: 50–54.
12. Diepgen TL, Sauerbrei W, fartasch M. Development and 
validation of diagnostic scores for atopic dermatitis incor-
porating criteria of data quality and practical usefulness. J 
Clin Epidemiol 1996; 49: 1031–1038.
13. finlay AY, Khan gK. Dermatology Life Quality Index 
(DLQI) – a simple practical measure for routine clinical 
use. Clin Exp Dermatol 1994; 19: 210–216.
14. Hongbo Y, Thomas CL, Harrison MA, Salek MS, finlay 
AY. Translating the science of quality of life into practice: 
What do dermatology life quality index scores mean? J 
Invest Dermatol 2005; 125: 659–664.
15. de Souza MP, Rangel Miller V. Significance of patient 
registries for dermatological disorders. J Invest Dermatol 
2012; 132: 1749–1752.
16. Skudlik C, Weisshaar E, Scheidt R, Elsner P, Wulfhorst B, 
Schonfeld M, et al. First results from the multicentre study 
rehabilitation of occupational skin diseases – optimization 
and quality assurance of inpatient management (ROQ). 
Contact Dermatitis 2012; 66: 140–147.
17. Weisshaar E, Skudlik C, Scheidt R, Matterne u, Wulfhorst 
B, Schonfeld M, et al. Multicentre study ‘rehabilitation 
of occupational skin diseases – optimization and quality 
assurance of inpatient management (ROQ)’-results from 
12-month follow-up. Contact Dermatitis 2013; 68: 169–174.
18. Wallenhammar LM, Nyfjall M, Lindberg M, Meding b. 
Health-related quality of life and hand eczema – a compa-
rison of two instruments, including factor analysis. J Invest 
Dermatol 2004; 122: 1381–1389.
19. Agner T, Andersen kE, Brandao FM, Bruynzeel DP, Bruze 
M, Frosch P, et al. Hand eczema severity and quality of 
life: a cross-sectional, multicentre study of hand eczema 
patients. Contact Dermatitis 2008; 59: 43–47.
20. Hutchings CV, Shum KW, gawkrodger DJ. Occupational 
contact dermatitis has an appreciable impact on quality of 
life. Contact Dermatitis 2001; 45: 17–20.
21. Cvetkovski RS, Zachariae R, Jensen H, Olsen J, Johansen 
JD, Agner T. Quality of life and depression in a population 
of occupational hand eczema patients. Contact Dermatitis 
2006; 54: 106–111.
22. Lau MY, Matheson MC, burgess JA, Dharmage SC, Nixon 
R. Disease severity and quality of life in a follow-up study 
of patients with occupational contact dermatitis. Contact 
Dermatitis 2011; 65: 138–145.
23. Coenraads PJ. Hand eczema is common and multifactorial. 
J Invest Dermatol 2007; 127: 1568–1570.
24. kaae J, Menne T, Carlsen BC, zachariae C, Thyssen JP. The 
hands in health and disease of individuals with filaggrin 
loss-of-function mutations: clinical reflections on the hand 
eczema phenotype. Contact Dermatitis 2012; 67: 119–124.
Acta Derm Venereol 93
Supplementary material to article by C. Apfelbacher et al. ”Characteristics and Provision of Care in Patients with Chronic Hand Eczema: 
Updated Data from the CARPE Registry”
Dermatology practices: Wilhelm Akst, Prüm; Dr Sabine An-
ders-Ankerholt, Munich; Dr Stefanie Baum, kassel; Dr Simone 
baumann, Leipzig; Dr Ann baumgartner, freiburg; Dipl-Med 
kerstin Bock, Cottbus; Dr Joachim Bockhorst, Dülmen; Dr 
Martin böhm, Ludwigshafen; Marion büttner, Oberursel (Dr 
Liesl Häussermann-Mangold); Dr Elmar Ehring, Münster; Dr 
Christina Engels, Aachen; Dr Thomas-Matthias Ernst, Berlin; 
Dr Walter Frisch, Frankfurt a. M; PD Dr Sylke Gellrich, Berlin; 
Dr Christine Gißler-Walter, Mutterstadt; Dr Susanne Gleißner, 
Wuppertal; Dr ulrich Gössinger, korbach; Waldemar Grosch, 
Kulmbach; Dr Agnes grünenwald, dermaven-mvz, Leipzig; 
Dr frank Häger, Marne; Dr Urte Hammann, Stade; Dr Sibylle 
Haueisen, Regensburg; Dr Susanne Heinisch, Höchstadt; Dipl-
Med Andreas Heinrich, Landsberg; Dipl.-Psych. Dr med. 
Johannes Hockmann, Oelde; Josephine Kaufmann, Jena (Dr 
Christine zollmann); Dr Wolfram keilig, Munich; Dipl-Med 
Marion kingl, Finsterwalde; Dr katrin kluge, Rehau; Dr 
Jürgen Knauber, Pirmasens; Dr Reinhard Knöll, Lüneburg; 
Dr Christian kors, Berlin; Maria kosinski, Bielefeld; Dr Su-
sanne Kühne, Magdeburg; Dr Michael Lau, Heide; Dr Joachim 
Lehmann, biberach; Dr Claudia Link, grünwald; Dr Michael 
Loth, gernsbach; Dr Hans-Joachim Lüdcke, Potsdam; Wolf-
gang Lutz, Ingolstadt; Dr Kathrin Mörstedt, bad Wörishofen; 
Dr Jürgen Nekwasil, Nordhausen; Dipl-Med Kathrin Neubert, 
burgstädt; Dr Marcus Nippesen, bünde; Ch. Nolting-Schräer, 
Lüdinghausen; Dr bernd Pfeil, Leipzig; Susanne Riehl, Dres. 
Dorittke/kardorff, Mönchengladbach; Dr Barbara Roberg, 
Xanten; Dr Ralph Salzmann, St Wendel; Dr Renate Schlegel 
Gomez, Bielefeld; Dr uwe Schlehaider, Burghausen; Dr Hend-
rik Schnabel, Offenburg; Dr Stefan Schröpfer, glückstadt; Dr 
Ina Schulze, Markkleeberg; Dipl-Med Claudia Schütz, Berlin; 
Dr Thomas Stuhlert, Frankfurt a. M.; Professor Dr Christian 
Termeer, Stuttgart; Dipl-Med Jens Thieme, Artern; Dr Peter uhl, 
berlin; Dipl-Med Wilfried Vogel, Lübben; Dr Elfi Wahlländer, 
Hausham; Dipl-Med Elke Weiland, Berlin; Dr Axel Wilmer, 
Neustadt; Dres. Wittjen/Meinke/fechner, Oldenburg (Dr Holger 
Benthien); Dr Beate ziethen, Berlin.
Dermatology hospitals/skin protection centres: Dr Irena 
Angelova-fischer, Lübeck; Dr Karl-Christian Appl, berlin; Dr 
Claudia baldauf, bad Reichenhall (Dr Oliver Hirschsteiner); 
Professor Dr Andrea Bauer, Technical university of Dresden; 
Dr Maria blessinger, SLK-Clinics Heilbronn gmbH, Heilbronn 
(Professor Dr Harald Löffler); PD Dr Kristine breuer, Dermato-
logikum, Hamburg; Dr Soo-Jin Cha, university of Jena, Berlin; 
Professor Dr Peter Elsner, university of Jena; Dr konstantin 
Ertner, Nuremberg Hospital (Professor Dr Erwin Schultz); PD 
Dr uwe Hillen, university Hospital Essen (Professor Dr Dirk 
Schadendorf); Jochen Hoffmann, university of Heidelberg 
(Professor Dr Alexander Enk); Dr Andreas kleinheinz, Elbe 
klinikum Buxtehude; Malgorzata kolesnik, university of 
Magdeburg (Professor Dr Harald gollnick); Dr David Lieps, 
Ambulatory Healthcare Centre POLIKUM, berlin; Professor 
Dr Vera Mahler, university of Erlangen (Professor Dr Gerhard 
Schuler); Dr Sonja Molin, Ludwig Maximilian University, Mu-
nich (Professor Dr Dr h. c. Thomas Ruzicka); Dr Rodrigo Mota, 
university of Düsseldorf (Professor Dr Bernhard Homey); 
Jörg Niemeyer, Ambulatory Healthcare Centre, Nordhausen; 
Dr Michael Sachse, Hospital Bremerhaven-Reinkenheide, 
Bremerhaven (Dr Gunnar Wagner); Dr Wolfgang H. Schenk, 
Hospital Noderney; Dr H. Schwantes, Clinic for Occupational 
Diseases of the Employers’ Liability Insurance Associations, 
Falkenstein; Dr Arna Shab, W. Fresenius Clinic, Wiesbaden 
(Ingrid Strack); Professor Dr Christian Skudlik, Environme-
ntal Medicine and Health Theory, University of Osnabrück; 
Dr Stephanie Soost, Charité university Hospital, Berlin, 
(Professor Dr Margitta Worm); Dr Diamant Thaci, university 
of Frankfurt/Main (Professor Dr R. kaufmann); Dr Tsianakas, 
university Hospital Münster (PD Dr R. Brehler); Dr Ralph von 
kiedrowski, Company for Medical Study & Service Selters, 
Selters/Westerwald; Dr Nicola Wagner, Darmstadt Hospital (PD 
Dr Maurizio Podda); Anna Neubauer-Tsyrkunova, Dr Michal 
Gina, Professor Dr Elke Weisshaar, university of Heidelberg 
(Professor Dr Thomas Diepgen); Dr Ansgar Weyergraf, Bad 
Bentheim (Dipl.-kfm. klaus kinast); Professor Dr Maria za-
bel, Recklinghausen; Professor Dr Christos zouboulis, Dessau 
Medical Center, Dessau.
Furthermore, we are grateful to the team working at the co-
ordinating centre based in the Department of Clinical Social 
Medicine, Heidelberg: Annette Scheuermann (project secretary), 
Sabine Erhardt (project secretary), Elisabeth zimmermann (data 
management). We thank Dr Tittelbach (Hautnetz GmbH & Co. 
kG) for the maintenance of the web-based documentation module.
Acta Derm Venereol 93
